Waylivra is the only therapy licensed* to treat familial chylomicronemia syndrome (FCS), as an adjunct to diet in adult patients with genetically confirmed disease and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate (1)

Volanesorsen, sold under the brand name Waylivra, is a triglyceride-reducing drug. It is a second-generation [3] 2'-O-methoxyethyl (2'-MOE) chimeric antisense therapeutic oligonucleotide (ASO) [4] that targets the messenger RNA for apolipoprotein C 3 (apo-CIII).

Waylivra is a medicine used to treat familial chylomicronaemia syndrome (FCS), a genetic condition that gives rise to high levels of fats called triglycerides in the blood.

Aug 31, 2017 · Waylivra (volanesorsen) is a new drug in development for the treatment of familial chylomicronemia syndrome. Waylivra information includes news, clinical trial results and side effects.

Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

What is Waylivra and what is it used for? Waylivra is a medicine used to treat familial chylomicronaemia syndrome (FCS), a genetic condition that gives rise to high levels of fats called triglycerides in the blood.

Waylivra is an antisense oligonucleotide designed to inhibit the translation of apoC-III (1) By reducing ApoC-III*, Waylivra removes an inhibitor of triglyceride clearance, enabling triglyceride metabolism through an LPL-independent pathway in patients with FCS. 1.

Waylivra ® is the only therapy licensed* to treat familial chylomicronemia syndrome (FCS), as an adjunct to diet in adult patients with genetically confirmed disease and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate. 1

Apr 3, 2025 · Patients with the rare disease familial chylomicronemia syndrome (FCS) will be able to access treatment with Akcea’s Waylivra via the NHS, after a U-turn by NICE.

WAYLIVRA® (volanesorsen sodium) - Abbreviated Prescribing Information . For further prescribing information and before prescribing consult WAYLIVRA® Summary of Product Characteristics (SPC) WAYLIVRA®: Each ml contains 200 mg volanesorsen sodium, equivalent to 190 mg volanesorsen.